Edition:
United States

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

39.83USD
12:55pm EDT
Change (% chg)

$0.45 (+1.14%)
Prev Close
$39.38
Open
$39.70
Day's High
$40.50
Day's Low
$39.66
Volume
21,150
Avg. Vol
118,466
52-wk High
$46.12
52-wk Low
$24.32

Latest Key Developments (Source: Significant Developments)

Audentes Therapeutics Inc Files For Potential Mixed Shelf Offering, Size Not Disclosed
Thursday, 29 Mar 2018 05:14pm EDT 

March 29 (Reuters) - Audentes Therapeutics Inc ::AUDENTES THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.AUDENTES THERAPEUTICS INC SAYS IN ADDITION, OFFERING OF UP TO $150.0 MILLION OF COMMON STOCK.  Full Article

Audentes Therapeutics Q4 Loss Per Share ‍$0.82
Thursday, 8 Mar 2018 04:01pm EST 

March 8 (Reuters) - Audentes Therapeutics Inc ::AUDENTES THERAPEUTICS REPORTS FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.AUDENTES THERAPEUTICS INC - ‍PLAN TO FILE IND MID-2018 AND INITIATE A PHASE 1/2 CLINICAL TRIAL OF AT982 IN Q4 OF 2018​.AUDENTES THERAPEUTICS INC QTRLY LOSS PER SHARE ‍$0.82.AUDENTES THERAPEUTICS INC - ‍CURRENT CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS ARE PLANNED TO FUND OPERATIONS INTO SECOND HALF OF 2020​.  Full Article

Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro
Thursday, 4 Jan 2018 07:00am EST 

Jan 4 (Reuters) - Audentes Therapeutics Inc ::AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY.PLANS TO PROVIDE NEXT UPDATE ON INTERIM DATA FROM ASPIRO IN Q2 2018.TOTAL 6 ADVERSE EVENTS (AES) REPORTED IN ASPIRO, 2 OF WHICH WERE DETERMINED TO BE SERIOUS ADVERSE EVENTS (SAES).‍OF FOUR NON-SERIOUS ADVERSE EVENTS, TWO HAVE BEEN DETERMINED TO BE PROBABLY OR POSSIBLY TREATMENT-RELATED​.‍AUDENTES PLANS TO PROVIDE NEXT UPDATE ON INTERIM DATA FROM ASPIRO IN Q2 OF 2018​.  Full Article

Audentes Therapeutics Q3 ‍loss per share $ 0.88​
Tuesday, 14 Nov 2017 04:01pm EST 

Nov 14 (Reuters) - Audentes Therapeutics Inc :Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update.Audentes Therapeutics inc qtrly ‍loss per share $ 0.88​.  Full Article

Audentes Therapeutics gets fast track designation for its muscle disorder drug
Wednesday, 27 Sep 2017 08:00am EDT 

Sept 27 (Reuters) - Audentes Therapeutics Inc :Audentes Therapeutics announces rare pediatric disease and fast track designations for AT132 for the treatment of x-linked myotubular myopathy.Audentes Therapeutics Inc - ‍preliminary data from aspiro, phase 1/2 study of AT132, expected to be available in q4 of 2017​.Audentes Therapeutics Inc - ‍AT132 has also received orphan drug designation from both fda and european medicines agency​.  Full Article

Audentes Therapeutics commences dosing of first patient in phase 1/2 trial of AT132 for the treatment of x-linked myotubular myopathy
Thursday, 21 Sep 2017 08:00am EDT 

Sept 21 (Reuters) - Audentes Therapeutics Inc :Audentes Therapeutics announces dosing of first patient in ASPIRO, a phase 1/2 clinical trial of AT132 for the treatment of X-linked myotubular myopathy.Says ‍preliminary data from ASPIRO expected to be available in Q4 of 2017​.Says ‍Audentes plans to announce preliminary data from INCEPTUS in Q3 of 2017​.  Full Article

Audentes Therapeutics files for mixed shelf offering of up to $250 mln‍​
Tuesday, 8 Aug 2017 05:41pm EDT 

Aug 9 (Reuters) - Audentes Therapeutics Inc -:Audentes Therapeutics Inc files for mixed shelf offering of up to $250 million - sec filing‍​.  Full Article

Audentes Therapeutics qtrly loss per share $0.83
Thursday, 11 May 2017 08:00am EDT 

May 11 (Reuters) - Audentes Therapeutics Inc :Audentes therapeutics reports first quarter 2017 financial results and provides corporate update.Qtrly loss per share $ 0.83.Q1 earnings per share view $-0.92 -- Thomson Reuters I/B/E/S.Audentes therapeutics inc - research and development expenses were $14.6 million for q1 of 2017 compared to $7.9 million for same period in 2016.Audentes therapeutics inc - as of march 31, 2017, audentes had cash, cash equivalents and short-term investments of $81.7 million.Audentes therapeutics inc - current cash, cash equivalents and marketable securities are planned to fund operations into late 2019.Audentes therapeutics-on track to file inds to evaluate systemic administration of at982 for treatment of pompe disease, at307 for treatment of cpvt.  Full Article

Audentes Therapeutics says offering of 5.2 mln shares priced at $14.50/shr
Tuesday, 18 Apr 2017 08:18pm EDT 

April 18 (Reuters) - Audentes Therapeutics Inc ::Audentes Therapeutics announces pricing of public offering of common stock.Says public offering of 5.20 million common shares priced at $14.50 per share.  Full Article

Audentes Therapeutics files for common stock offering of about 4.8 mln shares
Monday, 17 Apr 2017 04:27pm EDT 

April 17 (Reuters) - Audentes Therapeutics Inc -:Files for common stock offering of about 4.8 million shares - sec filing.  Full Article

BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO

* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY